- DENOCI OP 60MG INJECTION is used in the treatment of the following condition: Osteoporosis. Osteoporosis is a condition where bones become weak and brittle, increasing the risk of fractures.
- Bone loss due to hormonal therapy in breast or prostate cancer. Certain cancer treatments can weaken bones, increasing the likelihood of fractures. DENOCI OP 60MG INJECTION helps in maintaining bone density.
- Multiple myeloma (cancer affects plasma cells in the bone marrow). This injection helps in managing bone-related problems in patients suffering from multiple myeloma.
- Bone metastases (cancer that spreads to bone). When cancer spreads to the bones, it can cause pain and fractures. DENOCI OP 60MG INJECTION helps in strengthening the bones and reducing these complications.
Sale!
DENOCI OP
DENOSUMAB INJECTION 60MG
2-8* C
| MRP | : |
|
| Price | : | ₹8,000.00 |
| You Save | : | ₹6,062.50 (43.11%) |
1 vial(s)
- DENOCI OP 60MG INJECTION contains Denosumab as its active ingredient. It is primarily used in the treatment of osteoporosis, a condition characterized by decreased bone density and increased risk of fractures. Additionally, it is prescribed to prevent skeletal-related events in patients with certain cancers, including multiple myeloma and bone metastases from solid tumors. DENOCI OP 60MG INJECTION functions by targeting and inhibiting RANK ligand, a protein that regulates the formation, function, and survival of osteoclasts, which are cells responsible for bone resorption. By inhibiting RANK ligand, DENOCI OP 60MG INJECTION reduces bone breakdown and increases bone density. Clinical studies have demonstrated that it significantly improves bone mineral density, thereby reducing the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Furthermore, it helps in delaying or preventing bone complications such as fractures, spinal cord compression, or the need for radiation therapy to the bone in cancer patients. Regular monitoring of kidney function may be recommended, especially in individuals with pre-existing kidney conditions.
- DENOCI OP 60MG INJECTION is contraindicated in individuals with known hypersensitivity to Denosumab or any of the excipients in the formulation. It’s crucial to ensure adequate calcium and vitamin D intake during treatment to prevent hypocalcemia (low calcium levels in the blood). DENOCI OP 60MG INJECTION is not indicated for use in children and adolescents due to the lack of safety and efficacy data in this age group. Caution should be exercised when administering DENOCI OP 60MG INJECTION to patients with pre-existing hypoparathyroidism, as it may exacerbate the condition. Patients should be monitored for signs and symptoms of hypocalcemia, and appropriate calcium and vitamin D supplementation should be provided. Before initiating treatment, healthcare providers should evaluate the patient’s medical history and current medications to identify any potential risks or drug interactions.
